CHICAGO MEDICAL RESEARCH, LLC.

Name: Tahir Azam Abbasi, MD

Email: tabbasi@cmrllc1.com

PROFESSIONAL EMPLOYMENT:

2021 - Present	Clinical Investigator, Chicago Medical Research, LLC, Orland Park, Illinois
2016 - 2019	Clinical Investigator, Apex Medical Research
2016 - 2019	Clinical Investigator, Chicago Clinical Research Institute
2016 - Present	Instructor, Medicine/Cardiology/Internal Medicine, University of Chicago
1995 - Present	Instructor, Midwestern University
1995 - 2011	Instructor, Medicine/Cardiology/Internal Medicine, Oak Forest Hospital, Cook County
1987 - Present	Attending Cardiologist, Ingalls Memorial Hospital / University of Chicago
1990 - Present	Attending Cardiologist, Advocate South Suburban Hospital
1990 - Present	Attending Cardiologist, St. Margaret Hospital, Hammond
1990 - Present	Attending Cardiologist, St. Bernard Hospital, Chicago
1992 - 2011	Director, Non-Invasive Cardiology, Oak Forest Hospital
1995 - Present	Attending Cardiologist, St. James Hospital, Olympia Fields

EDUCATION:

1972 - 1979	M.B.B.S./M.D., including rotating internship, Osmania Medical College, Hyderabad, India
1982 - 1985	Residency in Internal Medicine, St. Joseph Hospital / Northwestern University, Chicago, Illinois
1985 - 1987	Fellowship in Cardiovascular Medicine, Columbus Hospital / Northwestern University, Chicago, Illinois

LICENSE: American Board of Internal Medicine - Internal Medicine, 1996; recertified 2008
Medical Licensure - Illinois, and Florida

PROFESSIONAL MEMBERSHIP:

- American Academy of Preventive Cardiology

CLINICAL AND PROCEDURAL SKILLS:

Non-Invasive Electrocardiography, exercise and pharmacologic stress testing, Holter and event monitoring, pacemaker/ICD evaluation, and echocardiography.

Invasive Cardiac catheterization and angiography, intra-aortic balloon pump management, Swan-Ganz catheterization, arterial-line placement, dialysis-catheter placement, and temporary pacemaker placement.

LEADERSHIP AND COMMITTEE SERVICE:

2007 - Present	Committee service, Intensive Care / Cardiac Care Committee
1992 - 2011	Director, Non-Invasive Cardiology, Oak Forest Hospital
1990 - Present	Medical Director, Hammond Whiting Nursing Home
2015 - Present	Medical Director, Pine Crest Nursing Home

THERAPEUTIC AREA OF EXPERTISE:

Therapeutic Area	**Sub-Therapeutic Area**
Cardiology	Coronary Artery Disease, Acute Coronary Syndrome; Myocardial Infarction, Hypertension, Hyperlipidemia
Nephrology	Chronic Kidney Disease
Pain Management	Chronic low back pain
Orthopedics	Osteoarthritis
Endocrinology	Diabetes Mellitus Type II

CLINICAL TRIAL EXPERIENCE

1. **Protocol: 70033093AFL3002 (LIBREXIA-AF)** - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation.
2. **Protocol: 1378-0020 (EASi-HF Preserved)** - A Phase III Double-Blind, Randomised, Parallel-Group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) >=40%.
3. **Protocol: EX6018-4758 (ZEUS)** - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation.

4. **Protocol: EX6018-4914 (ATHENA)** - Effects of ziltivekimab versus placebo on heart failure symptoms and physical function in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.
5. **Protocol: EX6018-4915 (HERMES)** - Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation.
6. **Protocol: D6402C00012 (BalanceD-HF)** - A Phase III, Randomised, Double-Blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function.
7. **Protocol: D6972C00003 (ARCTIC)** - A Phase III, Randomised, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure.
8. **Protocol: CV0291001 (BMS-986435/MYK-224 HFpEF)** - A Phase 2A, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF).
9. **Protocol: C4291003 (BRANCH-HF)** - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948, in Adults With Heart Failure.
10. **Protocol: ALN-AGT01-008 / US0006 (ZENITH)** A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease.
11. **Protocol: ALN-AGT01-008 / US0096 (ZENITH)** - A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease.
12. **Protocol: 20230227 (MARITIME-HF)** - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity.
13. **Protocol: VS-041-102 (VS-041 HFpEF)** - A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF).
14. **Protocol: 1378-0018 (BI-Reduced)** - EASi-HF reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%
15. **Protocol: NN9490-8266 (POLARIS)** - Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).

16. **Protocol: NN9490-8266 (POLARIS)** - Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
17. **Protocol: NN9490-8665 (AMBITION)** - Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1-3 oral glucose-lowering medications (AMBITION 7).

SIGNATURE & DATE:

09/MAR/2026